AngioDynamics(US:ANGO)2024-10-03 12:05Financial Performance - AngioDynamics achieved pro forma revenue growth of 1.1% year-over-year[3] - MedTech segment pro forma revenue grew by 8.7% year-over-year[3] - Auryon sales reached $13.7 million, a 24.9% increase year-over-year[3] - AlphaVac sales amounted to $2.2 million, reflecting a 21.1% year-over-year growth[3] - The company reported a pro forma Adjusted EBITDA loss of ($0.2) million, an improvement from ($1.1) million in Q1 FY24[3] - Full Year Net Sales guidance is $282 - $288 million[28] Product & Regulatory Milestones - The Auryon System received CE Mark approval in Europe[3] - An FDA submission was filed for NanoKnife prostate indication[3] - The RECOVER-AV clinical trial was initiated[3] - Cumulative sales of Auryon are over $140 million since its launch in September 2020[5] - FDA 510(k) & CE Mark for PE was received for AlphaVac in Q4 FY24[13]